Which of the following is not true about abciximab?
a) Glycoprotein IIb/IIIa blocker
b) Orally active
d) Used as an ajunct in PCI
Abciximab is an intravenous glycoprotein IIb/IIIa blocker which is a monoclonal antibody, useful as an adjunct in percutaneous coronary intervention when there is a thrombus load in the coronary artery. Glycoprotein IIb/IIIa is the receptor in the final common pathway for platelet activation.